Company profile: Impulse Monitoring
1.1 - Company Overview
Company description
- Provider of intraoperative neurophysiologic monitoring solutions to hospitals and other healthcare facilities, offering insight into the nervous system during spinal, nerve, and brain-related surgeries. Solutions include IONM delivering real-time data and alerts to help reduce surgical risk, plus EEG, ECoG, EMG, and SSEP for diagnosis and intraoperative monitoring.
Products and services
- Intraoperative Neuromonitoring (IONM): Delivers real-time neurophysiological data and critical alerts during spinal, nerve, and brain surgeries to reduce surgical risk and minimize injury and post-operative deficits (real-time)
- Somatosensory Evoked Potentials (SSEP): Captures electrical responses after peripheral nerve stimulation to monitor sensory pathway integrity during surgery (intraoperative)
- Electromyography (EMG): Quantifies electrical activity from skeletal muscles to diagnose peripheral nerve dysfunction and enable peripheral nerve monitoring, mapping, and identification during surgery (intraoperative)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Impulse Monitoring
GeNeuro
HQ: Switzerland
Website
- Description: Provider of therapeutic monoclonal antibody drugs targeting human endogenous retroviral proteins for nervous system and autoimmune diseases. Portfolio includes Temelimab for Multiple Sclerosis and long-COVID neurological/psychiatric symptoms, the GNC-501 personalized trial in post-COVID W-ENV-positive patients, and a preclinical HERV-K Env antibody for sporadic ALS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeNeuro company profile →
Serina Therapeutics
HQ: United States
Website
- Description: Provider of proprietary polymer-based drug delivery and therapeutics, including the POZ Platform for programmable, targeted, continuous small-molecule delivery (IV/SC/IM); SER-252 for advanced Parkinson’s Disease; CNS small-molecule conjugates; POZ-lipid LNPs for mRNA immunology; and ADCs that increase DAR to improve efficacy, addressing cancer, inflammation, pain and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Serina Therapeutics company profile →
CuraSen Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for neurodegenerative diseases, developing orphan drugs including CST-103/CST-107, a combination therapy targeting cognitive symptoms and disease progression in Parkinson’s disease (Phase 2); CST-2032/CST-107 for Alzheimer’s disease with similar focus (Phase 2); and CST-3056, an alpha-1A adrenoceptor agonist in preclinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CuraSen Therapeutics company profile →
Keros Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical discovery, development, and commercialization of novel treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Keros Therapeutics company profile →
ANS Medical
HQ: United States
Website
- Description: Provider of neuromodulation devices, engaged in their design, development, and manufacture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ANS Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Impulse Monitoring
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Impulse Monitoring
2.2 - Growth funds investing in similar companies to Impulse Monitoring
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Impulse Monitoring
4.2 - Public trading comparable groups for Impulse Monitoring
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →